Active Pharmaceutical Ingredient Market Size to Surpass US$ 307.5 Billion Growth by 2034, Exhibit a CAGR of 4% |Fact.MR

The global active pharmaceutical ingredients market (医薬品原薬市場) is valued at US$ 207.9 billion in 2024 and is expected to reach US$ 307.5 billion by the end of 2034. It represents a constant growth and annual growth rate (CAGR) of 4% for ten years from 2024 to 2034.

Markets act as a fundamental cornerstone of the pharmaceutical industry and play an important role in achieving the therapeutic effect of drugs. Active pharmaceutical ingredients (API) are bioactive compounds that provide medicines with the necessary pharmacological effects, allowing them to be effective in the treatment of various diseases.

𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐚 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐓𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭:
https://www.factmr.com/connectus/sample?flag=S&rep_id=9124

The global API market is witnessing significant growth due to various factors such as increasing prevalence of chronic diseases, increasing demand for generic drugs, advancement in drug development technologies, and increasing focus on personalized medicine.

𝐆𝐫𝐨𝐰𝐢𝐧𝐠 𝐃𝐞𝐦𝐚𝐧𝐝 𝐟𝐨𝐫 𝐆𝐞𝐧𝐞𝐫𝐢𝐜 𝐃𝐫𝐮𝐠𝐬:

One of the major factors driving the growth of the API market is the growing demand for generic drugs. As patents on many brand-name drugs expire, pharmaceutical companies are focusing on developing generic versions of these drugs to meet the growing demand for affordable healthcare solutions. APIs are the key ingredients of generic drugs and their availability and cost-effectiveness play a crucial role in boosting market growth.

𝐒𝐡𝐢𝐟𝐭 𝐓𝐨𝐰𝐚𝐫𝐝𝐬 𝐎𝐮𝐭𝐬𝐨𝐮𝐫𝐜𝐢𝐧𝐠:

Pharmaceutical companies are increasingly outsourcing the manufacturing of APIs to specialized contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs). Outsourcing allows companies to benefit from cost savings, access specialized expertise, and streamline their operations. Additionally, outsourcing enables companies to focus on their core competencies such as drug discovery and commercialization while leveraging the capabilities of external partners for API manufacturing.

𝐈𝐧𝐜𝐫𝐞𝐚𝐬𝐢𝐧𝐠 𝐅𝐨𝐜𝐮𝐬 𝐨𝐧 𝐁𝐢𝐨𝐥𝐨𝐠𝐢𝐜𝐬:

Biologics, including monoclonal antibodies, peptides and recombinant proteins, represent a growing segment of the pharmaceutical market. Biological APIs are produced using complex biotechnological processes and require specialized manufacturing facilities. As the demand for biologics increases, more and more emphasis is placed on the development and production of biologically derived APIs. This trend offers opportunities for biopharmaceutical and biotechnology companies.

𝐑𝐞𝐠𝐮𝐥𝐚𝐭𝐨𝐫𝐲 𝐂𝐨𝐦𝐩𝐥𝐢𝐚𝐧𝐜𝐞 𝐚𝐧𝐝 𝐐𝐮𝐚𝐥𝐢𝐭𝐲 𝐀𝐬𝐬𝐮𝐫𝐚𝐧𝐜𝐞:

APIs are manufactured and distributed according to strict regulatory requirements and quality standards to ensure patient safety and product efficacy. Regulatory bodies such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) set strict guidelines for API manufacturing practices, including good manufacturing practices (GMP) and quality control measures. Compliance with these regulations is essential for API manufacturers to obtain regulatory approvals and maintain market credibility.

𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬:

Bristol-Myers Squibb Company
Pfizer Inc.
Boehringer Ingelheim
Cipla Inc.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline PLC
Hepalink Group
Merck & Co. Inc.
Sandoz International GmbH
Aurobindo Pharma Limited
Fresenius Kabi LLC
Teva Pharmaceutical Industries Ltd.
Sanofi
Novartis AG
Mylan N.V.
AbbVie, Inc.

𝐂𝐨𝐦𝐩𝐞𝐭𝐢𝐭𝐢𝐯𝐞 𝐋𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞:

The competitive environment for the active pharmaceutical ingredients (API) market is a dynamic mix of established pharmaceutical titans, contract manufacturing organizations (CMOs) and emerging entities competing for market position through innovation, strategic partnerships and global expansion.

Pfizer Inc. confirmed his commitment. . into US production in June 2022, injecting $120 million into its Kalamazoo, Michigan plant. This investment will facilitate the domestic production of its oral COVID-19 drug PAXLOVIDTM (nimatrelvir [PF-07321332] tablets and ritonavir tablets), increase production of nirmatrelvir API and registered precursors (RSM). The move is expected to create more than 250 new high-skilled jobs at Pfizer's Kalamazoo facility.

At the same time, Teva Pharmaceuticals is focusing investments in biologics manufacturing technology for APIs with similar biologics and new biologics. This strategic shift aligns with growing demand for biopharmaceutical products, positioning Teva Pharmaceuticals to take advantage of emerging market opportunities and strengthen its market presence.

𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧 𝐨𝐟 𝐀𝐜𝐭𝐢𝐯𝐞 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥 𝐈𝐧𝐠𝐫𝐞𝐝𝐢𝐞𝐧𝐭 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡

By API Type :
Small Molecules
Peptides & Oligonucleotides
Carbohydrate Drugs
Steroidal Drugs
Others

By Synthesis Type :
Biotech
Synthetic
By Manufacturer Type :
Captive APIs
Merchant APIs

By End User :
Pharmaceutical Companies
Biopharmaceutical Companies
CMOs
CDMOs

By Region :
North America
Latin America
Europe
East Asia
South Asia & Oceania
Middle East & Africa

𝐑𝐞𝐚𝐝 𝐌𝐨𝐫𝐞: https://www.factmr.com/report/active-pharmaceutical-ingredient-market

The global API market is witnessing significant growth due to factors such as increasing demand for generics, outsourcing trends, growth in biologics, regulatory compliance requirements, and technological advancements. As pharmaceutical companies continue to innovate and adapt to changing market dynamics, the API sector is expected to play a key role in shaping the future of the pharmaceutical industry.

𝐂𝐨𝐧𝐭𝐚𝐜𝐭:

US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232
Email: sales@factmr.com

𝐀𝐛𝐨𝐮𝐭 𝐅𝐚𝐜𝐭.𝐌𝐑

We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client's satisfaction.

This release was published on openPR.